Under the terms of the agreement, Grifols USA will market and sell AMDL Diagnostics's (ADI) DR-70 Onko-Sure cancer test for the monitoring of colorectal cancer (CRC) to hospitals, clinical labs, clinics, and other healthcare organizations throughout the US.
According to the agreed upon terms, Grifols USA has the rights to market and distribute ADI's Onko-Sure cancer test specifically for the monitoring of colorectal cancer in the US. This includes developing and implementing a marketing strategy to drive product awareness; educate clinical laboratories and physicians; and generate product sales.
Douglas MacLellan, chairman and CEO of Radient and ADI, said: "We are extremely pleased to announce a top-tier distribution partnership for our Onko-Sure cancer test in the US. We are dedicated to establishing a strong, long-lasting and highly successful relationship with the Grifols team - one that will help make Onko-Sure the standard in cancer testing and deliver direct value to our customers, patients, and shareholders."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index